GLP-1 receptor agonists are a class of medications used primarily to treat type 2 diabetes and, more recently, obesity. They work similarly to glucagon-like peptide-1 (GLP-1), a hormone that, in response to meals, promotes feelings of fullness, delays stomach emptying, inhibits glucagon release, and boosts insulin production. By enhancing insulin sensitivity and reducing appetite, these drugs help improve blood sugar homeostasis and may encourage weight loss. Common examples that have also shown cardiovascular advantages are ligarglutide and semaglutide.
Global GLP-1 Receptor Agonist Market Driving Factors and Challenges
Driving Factors- It is anticipated that the growing incidence of diabetes and obesity will propel this market's expansion. People who are overweight or obese are more likely to acquire diabetes and cardiovascular disease. Globally, obesity rates are on the rise, and it is generally agreed that this is one of the most important public health concerns of our day. The World Heart Federation estimates that about 2.3 billion people and children worldwide are overweight or obese. Furthermore, more than 90% of people with type 2 diabetes are overweight or obese to some extent, according to the Obesity Action Coalition (OAC). Thus, the global need for GLP-1 receptor agonist medications for therapy is being driven by the growing numbers of people with diabetes and obesity.
Challenges- The market's growth and accessibility for GLP-1 receptor agonists may be hampered by numerous issues. The high cost of these medications often hinders patient access, especially in places with less developed healthcare systems. Adverse effects, such as gastrointestinal issues, have also been brought up as a concern because they may deter patients from sticking to their treatment regimen. Competition from alternative diabetes and obesity treatments, including non-pharmacological methods and newer medications, makes matters more difficult. Regulatory barriers and the need for significant clinical data to demonstrate long-term safety and efficacy may potentially hinder the approval process for innovative formulations.
Impact of COVID-19 on Global GLP-1 Receptor Agonist Market
The COVID-19 pandemic had a significant impact on the global market for GLP-1 receptor agonists in a number of ways. In the beginning, the disruption of health care led to fewer patient visits and delayed diagnosis of obesity and diabetes, which in turn led to fewer new prescriptions for these medications. Disruptions to the supply chain also affected the availability of GLP-1 receptor agonists, resulting in shortages in some regions. On the other hand, the pandemic increased awareness of metabolic health and the necessity of managing these conditions because those with diabetes were more susceptible to COVID-19.
Global GLP-1 Receptor Agonist Market Key Players:
The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as: Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi.
Global GLP-1 Receptor Agonist Market Segmentation:
By Product: Based on the Product, Global GLP-1 Receptor Agonist Market is segmented as; Ozempic,k Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other.
By Application: Based on the Application, Global GLP-1 Receptor Agonist Market is segmented as; Type 2 Diabetes Mellitus, Obesity.
By Route of Administration: Based on the Route of Administration, Global GLP-1 Receptor Agonist Market is segmented as; Parenteral, Oral.
By Distribution Channel: Based on the Distribution Channel, Global GLP-1 Receptor Agonist Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.